Erica DiNapoli

Erica DiNapoli is an Assistant Editor for OncLive®. She joined the company in 2020 and now assists in editing and publishing both videos and informational articles to the website; she also helps manage the social media platforms. Prior to joining MJH Life Sciences, she was a student at Monmouth University and held two marketing internships at United Teletech Financial Federal Credit Union and Trendsetter Media & Marketing.

Articles

Sun Spotlights Advances Made in Advanced/Metastatic Gastric and GEJ Adenocarcinoma

November 16th 2020

Weijing Sun, MD, FACP, discusses the great need for effective first-line treatment options in advanced/metastatic gastric and GEJ adenocarcinoma.

Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing

November 7th 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Need for Germline Testing Becomes Increasingly Pronounced in Oncology

November 6th 2020

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

CDK4/6, PI3K Inhibition Among Top Advances Made in Metastatic Breast Cancer Treatment

November 3rd 2020

Julie M. Collins, MD, MPH, highlights key updates with targeted agents such as CDK4/6 and PI3K inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

ADAURA Generates Excitement for Targeted Therapy in Adjuvant EGFR+ NSCLC

November 2nd 2020

Balazs Halmos, MD, MS, highlights the significance of the ADAURA trial in EGFR-positive NSCLC, questions raised by these data, and other efforts being made in the adjuvant setting.

Frontline Maintenance Therapy Transforms Advanced Ovarian Cancer With PARP Inhibitors

October 30th 2020

Mae Zakhour, MD, discusses the rise of PARP inhibitors as frontline maintenance therapy in advanced ovarian cancer and the key data that supported these regulatory decisions.

Tan Speaks to Benefits of Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

October 30th 2020

Antoinette R. Tan, MD, discusses the FDA approval of the fixed-dose combination of SC pertuzumab and trastuzumab with hyaluronidase, in combination with IV chemotherapy in HER2-positive breast cancer.

Deeper Understanding of Disease Biology Needed in Melanoma to Move the Needle Forward

October 29th 2020

Jason J. Luke, MD, discusses the recent advancements with BRAF-targeted therapies and PD-1 checkpoint inhibitors in melanoma.

Martins Makes Sense of the Complicated Frontline NSCLC Treatment Landscape

October 29th 2020

Renato G. Martins, MD, discusses the many up-front approaches that have emerged in NSCLC, remaining questions to address with future efforts, and novel combinations under exploration.

Targeted Therapy Research Booms in Biomarker-Positive NSCLC

October 28th 2020

Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level.

Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC

October 28th 2020

Christina Baik, MD, MPH, highlights the evolving role of EGFR inhibition in the NSCLC space.

Cellular Therapies Move Forward in Lymphomas and Leukemias, But Challenges Remain

October 27th 2020

Abhinav Deol, MD, highlights the progress that has been made with CAR T-cell therapy in leukemia and lymphoma, challenges faced with regard to accessibility and toxicity, and next steps for this modality.

Cellular and Targeted Therapies Push the Envelope in Hematologic Malignancies

October 27th 2020

Jeffrey Zonder, MD, discusses the explosion of targeted therapies, along with the rise of cellular therapy, in hematologic malignancies.

Immunotherapy Combos Continue to Excel in NSCLC, But Patient Selection Must Be Optimized

October 23rd 2020

In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.

Subbiah Addresses Controversy Surrounding Pembrolizumab Approval for TMB-High Tumors

October 22nd 2020

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

Darolutamide/ADT Continues to Demonstrate Favorable Tolerability in Nonmetastatic CRPC

October 21st 2020

Neal D. Shore, MD, FACS, highlights the role of darolutamide plus androgen deprivation therapy and how it continues to demonstrate a highly favorable tolerability and safety profile in patients with nonmetastatic castration-resistant prostate cancer.

CTCs Serve as Prognostic Marker for Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

October 20th 2020

Amir Goldkorn, MD, discusses circulating tumor cell count, a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer.

Prostate Cancer Enters a New Era of Precision Medicine

October 20th 2020

Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the space.

Targeted Therapies Take Center Stage in the CLL Treatment Paradigm

October 14th 2020

Seema A. Bhat, MD, spotlights the advances that have been made with BTK inhibitors in chronic lymphocytic leukemia, shares emerging approaches under exploration, and forecasts where the field is headed.

Innovative Approaches Augment Sequencing in Prolific Multiple Myeloma Armamentarium

October 14th 2020

Sarah Nagle, MD, spotlights the critical role of targeted therapy in multiple myeloma.